Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | MITF | O75030 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CASP2 | P42575 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811290 | 0.85 | CSNK2A2 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4813580 | 0.80 | MAPT (0.48) | ALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL9481584 | 0.73 | MEN1 (0.39) | ALDH1A1NPC1RAB9AMEN1POLB | |
| SCHEMBL1970389 | 0.70 | POLB (0.56) | ALDH1A1SMN1; SMN2LMNAKDM4EGAA | |
| SCHEMBL1358344 | 0.70 | ACP1 (0.63) | SMN1; SMN2LMNANPC1RAB9ATHRB | |
| SCHEMBL5912479 | 0.70 | NPC1 (0.55) | ALDH1A1SMN1; SMN2LMNAKDM4ENPC1 | |
| SCHEMBL7093176 | 0.69 | NPC1 (0.58) | ALDH1A1SMN1; SMN2LMNAKDM4ENPC1 | |
| SCHEMBL11595205 | 0.69 | CGAS (0.48) | ALDH1A1SMN1; SMN2CGASLMNAKDM4E | |
| SCHEMBL1358076 | 0.68 | CGAS (0.47) | ALDH1A1SMN1; SMN2CGASLMNANPC1 | |
| SCHEMBL1358356 | 0.68 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0354757-A2 | Cephalosporins and homologous compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-02-14 | — | — | EP | claimed |
| EP-0265185-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | claimed |
| US-4490524-A | BACTERICIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1984-12-25 | — | — | US | claimed |
| US-7355040-B2 | Process for the preparation of cephalosporin compounds and synthetic intermediates | ZOETIS SERVICES LLC | 2008-04-08 | — | — | US | disclosed |
| EP-1178049-B1 | Process for the preparation of cephalosporin compounds and intermediates for the synthesis of these compounds | PFIZER (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050165229-A1 | Novel process | PFIZER, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-6825344-B2 | CYCLIZATION CEPHAM DERIVATIVE | PFIZER INC. | 2004-11-30 | — | — | US | disclosed |
| US-20020058806-A1 | Novel process | ZOETIS SERVICES LLC | 2002-05-16 | — | — | US | disclosed |
| EP-1178049-A1 | Process for the preparation of cephalosporin compounds and intermediates for the synthesis of these compounds | PFIZER INC. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0624160-B1 | 2-ISOCEPHEM AND OXACEPHEM DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0625984-B1 | CEPHALOSPORIN COMPOUNDS | PFIZER (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-0367124-A1 | Penicillanic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-05-09 | — | — | EP | disclosed |
| EP-0359536-A2 | Cephalosporin compounds, process for their preparation and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
| EP-0354757-A2 | Cephalosporins and homologous compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-02-14 | — | — | EP | disclosed |
| US-4771045-A | 2-oxozetidinone derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-13 | — | — | US | disclosed |
| EP-0265185-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| CN-85105120-A | The preparation method of novel cephalosporin derivatives | — | 1986-12-31 | — | — | CN | disclosed |
| CN-85105797-A | The preparation of antimicrobial compounds | — | 1986-08-27 | — | — | CN | disclosed |
| US-4490524-A | BACTERICIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1984-12-25 | — | — | US | disclosed |
| US-4490524-A | BACTERICIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165229-A1 | Novel process | CYP11B2, CCNB1, CYP11B1 | ALDH1A1 1333/4885SMN1; SMN2 2262/4885CGAS 1242/4885 |
| US-20020058806-A1 | Novel process | CYP4B1, CYP11B2, CYP11B1 | ALDH1A1 1283/4885SMN1; SMN2 1611/4885CGAS 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.